Amgen
About
Amgen Inc. (NASDAQ: AMGN) is one of the world's largest independent biotechnology companies, pioneering breakthrough therapies in oncology, cardiovascular disease, bone health, neuroscience, and inflammation with blockbuster drugs including Enbrel, Prolia, Otezla, Repatha, and the obesity treatment MariTide in its pipeline. Founded in 1980, the company has grown from a startup into a biotech giant with annual revenues exceeding $25 billion, driven by a robust portfolio of biologic medicines and a growing biosimilars business. As an investment, Amgen offers a rare combination for biotech of established profitability, generous dividends, and significant pipeline upside, particularly from its next-generation obesity and cardiovascular programs.
Biotech Stocks
Amgen is a cornerstone biotech stock representing one of the industry's most successful companies, with a deep pipeline of biologic therapies, a proven track record of bringing innovative medicines to market, and the scale to invest billions annually in research and development across multiple therapeutic areas.
Weight Loss Stocks
Amgen is developing MariTide, a promising next-generation obesity drug candidate that could compete in the rapidly growing weight loss therapeutics market alongside Eli Lilly and Novo Nordisk.
Key Financials AMGN
Price
$369.19
Change (1D)
+0.82%
Change (30D)
+12.80%
Change (60D)
+8.04%
Change (90D)
+25.52%
Change (180D)
+32.61%
Change (1Y)
+25.12%
Change (5Y)
+56.01%
P/E Ratio
22.03
EPS (TTM)
$16.76
52-Week Range
$261.43 — $385.12
50-Day MA
$338.01
Volume
2.41M
Data updated Feb 15 · Source: Twelve Data
